Opthea (OPT) announced three senior hires
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025
October 8, 2024 7:00 AM EDTParisa Zamiri, MD, PhD, and Tom Reilly respectively appointed CMO and CFO
Anand Sundaram appointed Vice President Marketing
MELBOURNE, Australia and PRINCETON, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, Opthea, the Company), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced three senior hires as the Company continues to prepare for the sozinibercept Phase 3 topline data readouts of COAST anticipated in early Q2 calendar year 2025 and ShORe in mid calendar year... More
